Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S1PR1 siRNA is a **small interfering RNA** specifically designed to bind and degrade the messenger RNA of **Sphingosine-1-phosphate receptor 1 (S1PR1/EDG1)**, effectively silencing the expression of this G-protein-coupled receptor. S1PR1 is involved in the regulation of immune cell trafficking, vascular growth, and neuronal excitability. Knocking down S1PR1 with siRNA has been shown to reduce S1PR1 protein expression, suppress inflammatory responses, and inhibit processes such as angiogenesis, tumor growth, neuroinflammation, and nociceptive pain signaling[2][3][4]. Experimental use of S1PR1 siRNA demonstrates its ability to modulate disease states by preventing S1PR1-mediated cellular activation and subsequent pro-inflammatory and pro-nociceptive effects[2][3][4]. S1PR1 siRNA is primarily used as a research tool, notably in preclinical studies of pain, inflammation, neurobiology, vascular biology, and cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S1PR1 siRNA.